Horien Biochemical Technology Co., Ltd.
TTPEX:781428.30
TWD
0.00
(0.00%)
Horien Biochemical Technology Co., Ltd.
TPEX:7814
(Taipei Exchange)
Recent
price
28.30
P/E
ratio
277.81
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- Horien Biochemical Technology Co., Ltd. is a Taiwan-based biotechnology and medical device company primarily engaged in the research, development, manufacture, and distribution of ophthalmic products, biomedical materials, and contact lens care solutions. The company operates within the biotechnology and healthcare sector, catering to optical retailers, ophthalmic clinics, pharmaceutical distributors, and international healthcare brands through proprietary brand sales as well as original equipment manufacturing (OEM) and original design manufacturing (ODM) arrangements. Its comprehensive product portfolio includes soft contact lenses, comprising daily disposable, weekly, monthly, toric, multifocal, and cosmetic color contact lenses, as well as high-oxygen-permeability silicone hydrogel lenses; contact lens care products, consisting of multi-purpose disinfecting solutions, rewetting drops, saline rinses, and enzymatic cleaning agents; ophthalmic biomaterials and surgical devices, including sodium hyaluronate ophthalmic viscosurgical devices (OVD), lubricating eye drops, and dry eye relief formulations; and medical aesthetic and wound care products, featuring hyaluronic acid dermal fillers, post-procedure skincare treatments, and bio-cellulose medical dressings. Horien Biochemical Technology distributes its products domestically in Taiwan and exports across Greater China, Southeast Asia, Japan, Europe, and North America. In recent developments, the company advanced its public market presence by listing on the Emerging Stock Board of the Taipei Exchange (TPEx: 7814) in Taiwan. Over the past two years, the company has expanded automated manufacturing facilities to scale production capacity, broadened international medical device regulatory certifications including ISO 13485 and CE mark approvals, deepened strategic OEM/ODM partnerships with global optical chains, and accelerated research and development initiatives focused on next-generation silicone hydrogel contact lens technologies and advanced ophthalmic regenerative biomaterials. Founded in 2011 and headquartered in Taichung, Taiwan, Horien Biochemical Technology Co., Ltd. operates as a specialized vision care and biomaterials enterprise within the broader Ginko healthcare ecosystem.